Last reviewed · How we verify
recombinant human erythropoietin
Recombinant human erythropoietin, developed by the University of Aarhus, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and mechanism of action, which addresses a significant unmet need in its primary indication. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | recombinant human erythropoietin |
|---|---|
| Also known as | rhEPO, EPO, Epoetin beta, EPO, Eprex, epocaine |
| Sponsor | University of Aarhus |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia (PHASE4)
- Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis (PHASE4)
- Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients (PHASE4)
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Perioperative Blood Conservation: Role of Combined Iron Supplementation Protocols in Reducing Allogeneic Transfusion (NA)
- Impact of Erythropoietin on Hematological Adaptations and Physical Performance (PHASE4)
- Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies (PHASE2)
- Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- recombinant human erythropoietin CI brief — competitive landscape report
- recombinant human erythropoietin updates RSS · CI watch RSS
- University of Aarhus portfolio CI